
    
      CLEAR is a phase IV, multi-centric, prospective, observational study to assess the clinical
      efficacy and safety of Leflunomide as first-line therapy and as add-on therapy to other
      DMARDs (such as Methotrexate, Hydroxychloroquine, Sulfasalazine) with or without Steroids use
      in Egyptian patients with Active Rheumatoid Arthritis.
    
  